6.50
Immuneering Corp stock is traded at $6.50, with a volume of 2.28M.
It is up +6.38% in the last 24 hours and up +9.24% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.11
Open:
$6.24
24h Volume:
2.28M
Relative Volume:
1.52
Market Cap:
$270.21M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.4392
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+2.20%
1M Performance:
+9.24%
6M Performance:
+420.00%
1Y Performance:
+171.97%
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMRX
Immuneering Corp
|
6.50 | 386.39M | 317.00K | -53.47M | -49.31M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
Mar-15-24 | Reiterated | Needham | Buy |
Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Dec-01-23 | Initiated | Needham | Buy |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-30-23 | Initiated | Mizuho | Neutral |
Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
Apr-01-22 | Initiated | Oppenheimer | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Insider Stock Purchases: October 07, 2025 - Quiver Quantitative
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat
Why Immuneering Corporation stock is in analyst buy zoneEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Two new option listings and three option delistings on October 2nd - TipRanks
Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World
Insider Stock Purchases: October 01, 2025 - Quiver Quantitative
Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey
Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Can Immuneering Corporation stock sustain market leadershipEarnings Performance Report & Reliable Breakout Forecasts - newser.com
Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World
Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria
Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com
Immuneering to host call on pancreatic cancer treatment data - Investing.com
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times
First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan
Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World
To vanquish pancreatic at last? Immuneering scores in phase II - BioWorld MedTech
Immuneering Stock Rises 21.7% on Supply Agreement With LLY - MSN
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst (IMRX) - Seeking Alpha
Mizuho reiterates Outperform rating on Immuneering stock after positive data - Investing.com India
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months - NewsBreak: Local News & Alerts
IMRX: Oppenheimer Raises Target Price Amidst Outperform Rating | - GuruFocus
Oppenheimer Forecasts Strong Price Appreciation for Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Immuneering Corporation’s Stock Rollercoaster: What’s Next? - StocksToTrade
Immuneering price target raised to $30 from $21 at Oppenheimer - TipRanks
Oppenheimer Maintains Immuneering(IMRX.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Immuneering Corporation (IMRX) PT Raised to $30 at Oppenheimer - StreetInsider
Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX) - StreetInsider
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket - Benzinga
Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Immuneering Announces $25M Securities Purchase Agreement - TipRanks
Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering - TipRanks
IMRX Soars On Pancreatic Cancer Data, PEPG Sets DM1 Splicing Correction Record, CLPT On Watch - RTTNews
Immuneering Reveals Pricing Of 18.96 Mln Shares Public Offering At $9.23/Shr - Nasdaq
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
Feinberg Peter | Director |
Sep 29 '25 |
Buy |
7.18 |
5,000 |
35,900 |
141,766 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):